Developer docs
API playgroundTry for free, no card

Search company profiles

TAG1

Full company profile

uuid0026fwk

Namestring
TAG1
Legal namestring
TAG1 Inc.
Websiteurl
tag1inc.com
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersChesterfield, United States
HQ citystring
Chesterfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical radioisotope supply, targeted alpha therapy, Lead-212 generator, radiopharmaceutical isotopes, nuclear medicine manufacturing
Industry5 codes
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceuticals / Medical Isotopes
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Generator Sales and Isotope Supply
TypeHardware Sales
Description

TAG1 supplies its proprietary Lead-212 generators to biotech companies, hospital networks, and research institutions. The company also provides high-purity Lead-212 isotopes directly to enable pre-clinical and clinical research programs.

tag1inc.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TAG1 designs, manufactures, and supplies its proprietary portable Targeted Alpha Generator 1 (TAG1) system, which produces high-purity Lead-212 (Pb-212) medical radioisotopes from Radium-224 parent isotope. The generator enables nuclear radiopharmacies, hospital networks, and research institutions to generate their own on-site Lead-212 supply for Targeted Alpha Therapies in oncology, and the company also supplies Lead-212 isotopes directly to biotech and pharmaceutical innovators for pre-clinical and clinical programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • TAG1 has met all critical to quality parameters to reliably provide pre-clinical quantities of Lead-212
Product overview1 text field

TAG1 is a medical isotope company offering a single core product: the proprietary Targeted Alpha Generator 1 (TAG1). This portable generator system produces Lead-212 (Pb-212) isotopes using Radium-224 as the parent isotope. The product enables nuclear radiopharmacies, large hospital networks, and research institutions to generate their own on-site supply of high-purity Lead-212 for targeted alpha therapies in cancer treatment. TAG1 also provides the Lead-212 isotope itself as a service component, along with partnership-based access to their generator technology for pre-clinical and clinical trials.

Product and service2 records
1Targeted Alpha Generator 1 (TAG1)
CategoryMedical isotope generation hardware
Description

Proprietary portable generator system designed to produce Lead-212 (Pb-212) isotopes for targeted alpha therapies in cancer treatment. Uses Radium-224 as its parent isotope and enables nuclear radiopharmacies, hospital networks, and research institutions to produce their own supply of Lead-212 isotopes on-site.

2High-Purity Lead-212 (Pb-212) Isotope Supply
CategoryMedical isotope supply services
Description

Direct supply of high-purity Lead-212 isotopes to small biotech and pharmaceutical companies, as well as research institutions, to enable pre-clinical and clinical research programs in targeted alpha therapies for oncology.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

TAG1 and NRG PALLAS signed a Letter of Intent (LOI) to jointly advance access to Lead-212 for next-generation cancer therapies across Europe. The partnership combines TAG1's portable Lead-212 generator with NRG PALLAS' Radium-224 production capabilities from their High Flux Reactor in Petten, Netherlands. NRG PALLAS will continue delivering high-purity Ra-224 to TAG1 through 2028, with plans to establish a secure, stable, and open supply platform for Lead-212 throughout Europe. The collaboration supports the Netherlands' Lead4Life initiative for developing Lead-212-based radiopharmaceuticals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-02
Description

TAG1 announced a strategic collaboration with the Molecular Cancer Imaging Facility (MCIF) at Dana-Farber Cancer Institute to accelerate development of targeted alpha therapies. TAG1 supplies its proprietary Lead-212 generator technology to enable pre-clinical and clinical research. The collaboration supports both early-stage discovery and translational research, with MCIF researchers gaining access to Lead-212 for testing novel compounds. The partnership aims to democratize Lead-212 supply and create pathways for innovators to advance their compounds.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

Expanded strategic partnership including a multi-year agreement supporting Radium-224 supply for both US-based and Europe-based Lead-212 generator production. The agreement enables further development and deployment of TAG1's proprietary Lead-212 generator platform in Europe, addressing the growing demand for decentralized isotope access and supporting alpha therapy development in oncology.

Strategic tierSupportingTypeOthers
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TAG1

Radiopharmaceuticals / Medical Isotopestag1inc.com

TAG1 firmographics

Firmographics
Name
TAG1
Legal name
TAG1 Inc.
Website
https://tag1inc.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

TAG1 industry classification

Industry
Product category
Radiopharmaceuticals / Medical Isotopes
NAICS
Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Medical radioisotope supply
  • Targeted alpha therapy
  • Lead-212 generator
  • Radiopharmaceutical isotopes
  • Nuclear medicine manufacturing

Where TAG1 is headquartered

Location

Headquarters

HQ city
Chesterfield
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TAG1 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

  1. Generator Sales and Isotope Supply: TAG1 supplies its proprietary Lead-212 generators to biotech companies, hospital networks, and research institutions. The company also provides high-purity Lead-212 isotopes directly to enable pre-clinical and clinical research programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

TAG1 product offering

Product offering

Core offering

TAG1 designs, manufactures, and supplies its proprietary portable Targeted Alpha Generator 1 (TAG1) system, which produces high-purity Lead-212 (Pb-212) medical radioisotopes from Radium-224 parent isotope. The generator enables nuclear radiopharmacies, hospital networks, and research institutions to generate their own on-site Lead-212 supply for Targeted Alpha Therapies in oncology, and the company also supplies Lead-212 isotopes directly to biotech and pharmaceutical innovators for pre-clinical and clinical programs.

Product overview

TAG1 is a medical isotope company offering a single core product: the proprietary Targeted Alpha Generator 1 (TAG1). This portable generator system produces Lead-212 (Pb-212) isotopes using Radium-224 as the parent isotope. The product enables nuclear radiopharmacies, large hospital networks, and research institutions to generate their own on-site supply of high-purity Lead-212 for targeted alpha therapies in cancer treatment. TAG1 also provides the Lead-212 isotope itself as a service component, along with partnership-based access to their generator technology for pre-clinical and clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Targeted Alpha Generator 1 (TAG1) Proprietary portable generator system designed to produce Lead-212 (Pb-212) isotopes for targeted alpha therapies in cancer treatment. Uses Radium-224 as its parent isotope and enables nuclear radiopharmacies, hospital networks, and research institutions to produce their own supply of Lead-212 isotopes on-site.
  • High-Purity Lead-212 (Pb-212) Isotope Supply Direct supply of high-purity Lead-212 isotopes to small biotech and pharmaceutical companies, as well as research institutions, to enable pre-clinical and clinical research programs in targeted alpha therapies for oncology.

Quantifiable outcome

  • TAG1 has met all critical to quality parameters to reliably provide pre-clinical quantities of Lead-212

Companies that use TAG1

Customer profile

Segments4 records

Ideal customer profiles4 records

TAG1 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

TAG1 partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and supporting.

  • NRG PALLAS B.V.flagshipStrategic or Co-development Partner · 22 April 2026TAG1 and NRG PALLAS signed a Letter of Intent (LOI) to jointly advance access to Lead-212 for next-generation cancer therapies across Europe. The partnership combines TAG1's portable Lead-212 generator with NRG PALLAS' Radium-224 production capabilities from their High Flux Reactor in Petten, Netherlands. NRG PALLAS will continue delivering high-purity Ra-224 to TAG1 through 2028, with plans to establish a secure, stable, and open supply platform for Lead-212 throughout Europe. The collaboration supports the Netherlands' Lead4Life initiative for developing Lead-212-based radiopharmaceuticals.
  • Dana-Farber Cancer Institute (Molecular Cancer Imaging Facility)coreStrategic or Co-development Partner · 2 March 2026TAG1 announced a strategic collaboration with the Molecular Cancer Imaging Facility (MCIF) at Dana-Farber Cancer Institute to accelerate development of targeted alpha therapies. TAG1 supplies its proprietary Lead-212 generator technology to enable pre-clinical and clinical research. The collaboration supports both early-stage discovery and translational research, with MCIF researchers gaining access to Lead-212 for testing novel compounds. The partnership aims to democratize Lead-212 supply and create pathways for innovators to advance their compounds.
  • NRG PALLAS B.V.flagshipStrategic or Co-development Partner · 27 October 2025Expanded strategic partnership including a multi-year agreement supporting Radium-224 supply for both US-based and Europe-based Lead-212 generator production. The agreement enables further development and deployment of TAG1's proprietary Lead-212 generator platform in Europe, addressing the growing demand for decentralized isotope access and supporting alpha therapy development in oncology.
  • Lead4Life InitiativesupportingOthers

Scale indicators3 records

Recent moves3 records

Expansion highlights3 records

TAG1 competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

TAG1 social profiles

Digital presence

TAG1 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TAG1 leadership team

Management profile

Number of profiles

Profiles1 record

TAG1 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TAG1 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TAG1

What does TAG1 do?

TAG1 designs, manufactures, and supplies its proprietary portable Targeted Alpha Generator 1 (TAG1) system, which produces high-purity Lead-212 (Pb-212) medical radioisotopes from Radium-224 parent isotope. The generator enables nuclear radiopharmacies, hospital networks, and research institutions to generate their own on-site Lead-212 supply for Targeted Alpha Therapies in oncology, and the company also supplies Lead-212 isotopes directly to biotech and pharmaceutical innovators for pre-clinical and clinical programs.

Is TAG1 a public or private company?

TAG1 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was TAG1 founded?

TAG1 was founded in 2024. It employs 1 to 10 people.

Where is TAG1 based?

TAG1 is headquartered in Chesterfield, United States, in the North America region.

How does TAG1 make money?

One revenue line is on record: generator Sales and Isotope Supply.

Does TAG1 have an API?

No public API is recorded for TAG1.

What industry is TAG1 in?

TAG1's product category is Radiopharmaceuticals / Medical Isotopes. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 334517 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceTAG1 and NRG PALLAS to Expand Lead-212 SupplyTAG1 and NRG PALLAS signed a Letter of Intent to jointly advance Lead-212 supply for European cancer therapies. The partnership combines TAG1's portable generator with NRG PALLAS' Radium-224 production, building on an existing Ra-224 supply through 2028. They aim to deliver pre-clinical and clinical quantities to oncology programs.PR NewswireTAG1 and NRG PALLAS to Expand Lead-212 SupplyTAG1 Inc. and NRG PALLAS B.V. announced a joint initiative to expand Lead-212 supply for cancer therapies across Europe, building on an existing supply arrangement through 2028. They plan to combine TAG1's portable Lead-212 generator with NRG PALLAS's Radium-224 production to meet industry demand, supporting the broader Lead4Life program and advancing radiopharmaceutical development.PR NewswireTAG1 Announces Strategic Collaboration to Advance Targeted Alpha TherapiesTAG1 Inc. announced a strategic collaboration with the Molecular Cancer Imaging Facility at Dana-Farber Cancer Institute to accelerate the development of targeted alpha therapies for cancer treatment, with TAG1 supplying its proprietary Lead-212 generator technology to enable pre-clinical and clinical research. The partnership aims to expand global access to Lead-212, an important radionuclide used in targeted alpha therapies, and will support a portfolio of research programs while creating opportunities for companies developing these therapies. The collaboration is expected to advance Dana-Farber's mission of developing transformative cancer treatments through combined isotope supply capabilities and scientific expertise.Towards HealthcareCDMO Services for Pharma and Biotech Market Expands in 2025 as Small Molecules Lead with 58.2%The global CDMO services market for pharma and biotech is expanding significantly, driven by increasing outsourcing trends and rising demand for cancer treatments. Small molecules dominated the market with a 58.2% share in 2024, while North America held the largest regional share at 44.1%. Key industry developments include strategic collaborations between entities like TAG1 Inc. and PharmaLogic, as well as acquisitions such as PCI Pharma Services' purchase of Ajinomoto Althea.